Revenue
2024
2025
Humacyte, Inc. (HUMA)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | — | — | — | — |
| Research & development | $69.3M | $88.6M | $76.5M | $63.3M | $61.3M | $54.1M |
| Operating expenses | — | $114.4M | $100.0M | $86.1M | $82.5M | $66.1M |
| Operating income | −$108.1M | −$114.4M | −$100.0M | −$84.6M | −$81.2M | −$64.6M |
| Net income | −$40.8M | −$148.7M | −$110.8M | −$12.0M | −$26.5M | −$66.5M |
| Basic EPSper diluted share | -$0.26 | -$1.26 | -$1.07 | -$0.12 | -$0.66 | -$11.54 |
| Diluted EPSper diluted share | -$0.26 | -$1.26 | -$1.07 | -$0.12 | -$0.66 | -$11.54 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 19, 2026Form 4 | Sebelius KathleenDirector | BuyCommon Stock | 56.8K | $0.88 | $50.0K | 148.0K |
| May 18, 2026Form 4 · 10b5-1 | Parikh Shamik JChief Medical Officer | SellCommon Stock | 45.9K | $0.90 | $41.3K | 272.7K |
| May 18, 2026Form 4 · 10b5-1 | Sander Dale A.CFO and Chief Corp. Dev. Off | SellCommon Stock | 45.9K | $0.90 | $41.3K | 267.2K |
| May 18, 2026Form 4 | Constantino Michael T.Director | BuyCommon Stock | 11.0K | $0.89 | $9.8K | 44.0K |
| Aug 20, 2025Form 4 | Dougan Brady WDirector | SellCommon Stock · indirect | 591.7K | $1.58 | $934.9K | 0 |